MedTrace Logo

Antiplatelet Secondary Prevention International Randomised Trial After INtracerebral HaemorrhaGe (ASPIRING)-Pilot Phase

NCT04522102 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-03-26

No results posted yet for this study

Summary

ASPIRING is an investigator-led, multicentre, prospective, randomised, open-label, blind outcome (PROBE), parallel group, clinical trial. The pilot phase will explore the feasibility of conducting a trial of starting antiplatelet monotherapy versus avoiding antiplatelet therapy for reducing all serious vascular events for adults surviving symptomatic stroke due to spontaneous intracerebral haemorrhage (ICH). The pilot phase will involve \~120 patients at \~30 hospitals in China, Australia and New Zealand.

Conditions

  • Intracerebral Hemorrhage

Interventions

DRUG

Start antiplatelet monotherapy

Start one antiplatelet drug, be available in local standard clinical practice, chosen by patient's physician pre-randomisation

Sponsors & Collaborators

  • University of Edinburgh

    collaborator OTHER

  • Huashan Hospital

    collaborator OTHER

  • The University of Western Australia

    collaborator OTHER

  • The George Institute for Global Health, China

    lead OTHER

Principal Investigators

  • Rustam Al-Shahi Salman · University of Edinburgh

  • Craig S Anderson · The George Institute

  • Graeme Hankey, MD · The University of Western Australia

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-03
Primary Completion
2023-10-13
Completion
2023-10-13

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04522102 on ClinicalTrials.gov